Home
Storia in 1 fonti
Eliminating KRAS: Why targeted protein degraders could redefine what’s possible in cancer
By Moitreyee Chatterjee-Kishore, Ph.D., MBA, Head of Oncology Development, Astellas Pharma Inc. | How targeted protein degraders could eliminate KRAS and redefine cancer care – insights from Astellas’ Head of Oncology Development
Raccontata da
fiercepharma.com
Timeline cronologica
- ·
AstraZeneca, Daiichi beat Gilead to first-line TNBC with FDA nod for Datroway
The TROP2 battle in first-line triple-negative breast cancer has officially kicked off. | A three-way battle among TROP2 ADCs in first-line triple-negative breast cancer is…
- ·
Eliminating KRAS: Why targeted protein degraders could redefine what’s possible in cancer
By Moitreyee Chatterjee-Kishore, Ph.D., MBA, Head of Oncology Development, Astellas Pharma Inc. | How targeted protein degraders could eliminate KRAS and redefine cancer care –…